<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954756</url>
  </required_header>
  <id_info>
    <org_study_id>APD-L0315</org_study_id>
    <nct_id>NCT03954756</nct_id>
  </id_info>
  <brief_title>Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer</brief_title>
  <official_title>Phase II Clinical Study of the Combination of Apatinib and PD1 in Treating Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With&#xD;
      PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus&#xD;
      Providing More Options for Patients With Advanced Gastric Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight&#xD;
      patients) iv every 2 weeks. The efficacy and safety will be observed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>up to 2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 2 year</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, and partial response (CR&#xD;
+ PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>up to 2 year</time_frame>
    <description>The time from the start of randomization to the first tumor recurrence/metastasis or the death of the subject for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>apatinib and PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib and PD1</intervention_name>
    <description>Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal&#xD;
PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.</description>
    <arm_group_label>apatinib and PD-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients join the study voluntarily, sign a consent form, have good compliance, and&#xD;
             comply with follow-up.&#xD;
&#xD;
          2. To be confirmed to meet the clinical diagnosis standard, histologically or&#xD;
             cytologically confirmed advanced Gastric Cancer.&#xD;
&#xD;
          3. Failure of the second-line standard treatment regimen (disease progression), &gt;14 days&#xD;
             from the last chemotherapy, chemotherapy regimen including fluorouracil (5-FU /&#xD;
             capecitabine / teggio), oxaliplatin and irinotecan; Acceptable or not received&#xD;
             bevacizumab/cetuximab/regofenib treatment.&#xD;
&#xD;
          4. Aged 18-70 years old, both genders.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.&#xD;
&#xD;
          6. Life expectancy of at least 3 months.&#xD;
&#xD;
          7. Patients must have at least 1 lesion that is measurable using RECIST v1.1 criteria.If&#xD;
             the lesion receiving local therapy (radiotherapy, radiofrequency, interventional&#xD;
             therapy, etc.) is the only lesion, definite imaging progress is required.&#xD;
&#xD;
          8. the main organ functions of the patient shall meet the following standards within 7&#xD;
             days before treatment：Blood routine examination standard (without blood transfusion&#xD;
             within 7 days before enrollment）Hemoglobin ≥ 70 g/L; Absolute neutrophil count (ANC)&#xD;
             ≥1.5×109/L; Platelet count ≥ PLT）≥80×109/L；Biochemical examination shall meet the&#xD;
             following standards:serum total bilirubin (TBIL)≤1.5 times the upper limit of normal&#xD;
             (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper&#xD;
             limit of normal(ULN)；Serum creatinine (Cr)≤1.5ULN or creatinine removal rate&#xD;
             (CCr)≥60ml/min；&#xD;
&#xD;
          9. Women of childbearing age should agree to use contraceptives (such as intrauterine&#xD;
             devices, contraceptives or condoms) during the study period and within 6 months after&#xD;
             the end of the study; the serum or urine pregnancy test is negative within 7 days&#xD;
             prior to study enrollment and must be Non-lactating patients; males should agree to&#xD;
             patients who must use contraception during the study period and within 6 months after&#xD;
             the end of the study period。&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypertension and unable to be controlled within normal level following treatment of&#xD;
             anti-hypertension agents(within 3 months): systolic blood pressure &gt; 140 mmHg,&#xD;
             diastolic blood pressure &gt; 90 mmHg；&#xD;
&#xD;
          2. Diabetes blood sugar control is poor；&#xD;
&#xD;
          3. Acute phase of cerebral infarction, or recovery period &lt;2 months；&#xD;
&#xD;
          4. Has a variety of factors that affect the absorption of oral drugs (such as inability&#xD;
             to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
          5. Patients with a risk of gastrointestinal bleeding may not be enrolled, including the&#xD;
             following: (1) active digestive ulcer lesions and fecal occult blood (++); (2) nausea&#xD;
             and hematemesis within 2 months Medical history. Simple fecal occult blood (+) is not&#xD;
             an exclusion criterion；&#xD;
&#xD;
          6. Coagulation abnormalities （INR&gt;1.5×ULN，APTT&gt;1.5×ULN）,with bleeding tendency;&#xD;
&#xD;
          7. Urine protein ≥ ++ or confirmed 24 hour urine protein quantitation &gt; 1.0 g；&#xD;
&#xD;
          8. Pregnant or lactating women;&#xD;
&#xD;
          9. Within 2 weeks after treatment with cytotoxic drugs and radiotherapy;Has taken two or&#xD;
             more oral targeted drugs；&#xD;
&#xD;
         10. Except for other malignant tumors, basal cell carcinoma of the skin and cervical&#xD;
             cancer in situ in the past 5 years；&#xD;
&#xD;
         11. The investigator believes that there are any conditions that may damage the subject or&#xD;
             result in the subject being unable to meet or perform the research request；&#xD;
&#xD;
         12. Patients with severe liver and kidney dysfunction (grade 4) should be excluded;&#xD;
&#xD;
         13. Those who are allergic to any component of apafitini mesylate should be excluded;&#xD;
&#xD;
         14. Mental disorders history, or psychotropic drug abuse history；&#xD;
&#xD;
         15. Previous use of regorafenib is not an exclusion criterion；&#xD;
&#xD;
         16. According to the investigator's judgment, there are people with concomitant diseases&#xD;
             that seriously endanger the safety of the patient or affect the patient's completion&#xD;
             of the study;&#xD;
&#xD;
         17. Surgery was performed within 4 weeks prior to the start of treatment, or patients with&#xD;
             major trauma or fractures. Or there is an unhealed wound before treatment;&#xD;
&#xD;
         18. Patients with severe heart disease, such as grade III or above (NYHA standard)&#xD;
             congestive heart failure, or grade III or above (CCS standard) angina, or a history of&#xD;
             myocardial infarction within 6 months prior to treatment, or an arrhythmia requiring&#xD;
             medication;&#xD;
&#xD;
         19. The patient has brain metastasis, meningeal metastasis;&#xD;
&#xD;
         20. Active HBV infection and rejection of formal antiviral therapy;&#xD;
&#xD;
         21. Active tuberculosis;&#xD;
&#xD;
         22. Participants who have participated in any drug or medical device clinical trial within&#xD;
             1 month prior to the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning Li</last_name>
    <phone>13526501903</phone>
    <email>lining97@126.com</email>
  </overall_contact>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

